Clinical Trial Update: Pharmacokinetics, Safety and Tolerability of the Combination of BI 207127 and Faldaprevir in Renal Impaired Patients [Phase 1]

View source ↗

Summary

Phase 1 study evaluating the pharmacokinetics, safety and tolerability of combining BI 207127 with faldaprevir in patients with renal impairment; the trial was …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Renal Insufficiency

Drugs mentioned

• BI 207127 (BI-207127)
• Faldaprevir (faldaprevir)

Snippet

Sponsor: Boehringer Ingelheim | Conditions: Renal Insufficiency | Phase 1 | Status: TERMINATED | Results posted: 2016-04-11